Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with...
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
About this item
Full title
Author / Creator
Papp, Kim A, Dr , Langley, Richard G, MD , Lebwohl, Mark, Prof , Krueger, Gerald G, Prof , Szapary, Philippe, MD , Yeilding, Newman, MD , Guzzo, Cynthia, MD , Hsu, Ming-Chun, PhD , Wang, Yuhua, PhD , Li, Shu, MS , Dooley, Lisa T, DrPH , Reich, Kristian, Prof , for the PHOENIX 2 study investigators and PHOENIX 2 study investigators
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Ustekinumab, a human monoclonal antibody against interleukins 12 and 23, has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing intensification in partial responders. Methods In this multicentre, phase III, double-blind, placebo-controlle...
Alternative Titles
Full title
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Authors, Artists and Contributors
Author / Creator
Langley, Richard G, MD
Lebwohl, Mark, Prof
Krueger, Gerald G, Prof
Szapary, Philippe, MD
Yeilding, Newman, MD
Guzzo, Cynthia, MD
Hsu, Ming-Chun, PhD
Wang, Yuhua, PhD
Li, Shu, MS
Dooley, Lisa T, DrPH
Reich, Kristian, Prof
for the PHOENIX 2 study investigators
PHOENIX 2 study investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_199016189
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_199016189
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(08)60726-6
